VivoSim Labs Inc (VIVS) USD0.001

Sell:$3.59Buy:$4.05$0.29 (7.97%)

Prices delayed by at least 15 minutes
Sell:$3.59
Buy:$4.05
Change:$0.29 (7.97%)
Prices delayed by at least 15 minutes
Sell:$3.59
Buy:$4.05
Change:$0.29 (7.97%)
Prices delayed by at least 15 minutes

Company Information

About this company

VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (NAM) models. The Company offers liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development. It uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The Company's 3D human tissue platform is multifaceted. The Company has expertise in 3D organoids, such as spheroids, and has made advances in proprietary cell culture techniques including ratios, components and conditions.

Key people

Keith E. Murphy
Executive Chairman of the Board, Corporate Secretary
Norman Staskey
President, Chief Financial Officer
Tony Lialin
Chief Commercial Officer
Douglas Jay Cohen
Lead Independent Director
David Gobel
Independent Director
Alison Tjosvold Milhous
Independent Director
Adam K. Stern
Independent Director
Click to see more

Key facts

  • EPIC
    VIVS
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US68620A3023
  • Market cap
    $9.98m
  • Employees
    5
  • Shares in issue
    2.60m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.